CA3123078A1 - Sulcardine administration for treatment of acute atrial fibrillation - Google Patents

Sulcardine administration for treatment of acute atrial fibrillation Download PDF

Info

Publication number
CA3123078A1
CA3123078A1 CA3123078A CA3123078A CA3123078A1 CA 3123078 A1 CA3123078 A1 CA 3123078A1 CA 3123078 A CA3123078 A CA 3123078A CA 3123078 A CA3123078 A CA 3123078A CA 3123078 A1 CA3123078 A1 CA 3123078A1
Authority
CA
Canada
Prior art keywords
sulcardine
pharmaceutically acceptable
acceptable salt
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3123078A
Other languages
English (en)
French (fr)
Inventor
Suzanne J. Romano
Gary T. Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Huya Bioscience International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Bioscience International LLC filed Critical Huya Bioscience International LLC
Publication of CA3123078A1 publication Critical patent/CA3123078A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3123078A 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation Pending CA3123078A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779056P 2018-12-13 2018-12-13
US62/779,056 2018-12-13
US201962858324P 2019-06-06 2019-06-06
US62/858,324 2019-06-06
PCT/US2019/066003 WO2020123824A1 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
CA3123078A1 true CA3123078A1 (en) 2020-06-18

Family

ID=69165588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3123078A Pending CA3123078A1 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Country Status (11)

Country Link
US (4) US11364223B2 (https=)
EP (1) EP3893870A1 (https=)
JP (1) JP2022514537A (https=)
KR (1) KR20210135990A (https=)
CN (1) CN113453677A (https=)
AU (1) AU2019397511B2 (https=)
CA (1) CA3123078A1 (https=)
IL (1) IL283931A (https=)
MX (1) MX2021006933A (https=)
WO (1) WO2020123824A1 (https=)
ZA (1) ZA202104166B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation
CN114984004B (zh) * 2022-05-25 2023-09-12 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
JP5308333B2 (ja) 2006-06-30 2013-10-09 シグマ−タウ レア ディジージズ エスィアー Ｌ−アスパラギナーゼｉｉを産生する組換え宿主
EP2468869B1 (en) 2007-01-31 2015-03-18 Pfenex Inc. Bacterial leader sequences for increased expression
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
EP2501381B1 (en) * 2009-11-17 2017-07-26 Huya Bioscience International LLC Treatment of atrial fibrillation
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
CN107532190B (zh) 2014-12-01 2021-07-09 菲尼克斯公司 用于肽生产的融合伴侣
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts

Also Published As

Publication number Publication date
IL283931A (en) 2021-07-29
AU2019397511A1 (en) 2021-07-22
MX2021006933A (es) 2021-09-30
US20250302805A1 (en) 2025-10-02
US20240115548A1 (en) 2024-04-11
US12357611B2 (en) 2025-07-15
WO2020123824A1 (en) 2020-06-18
AU2019397511B2 (en) 2025-08-21
CN113453677A (zh) 2021-09-28
US20200188357A1 (en) 2020-06-18
JP2022514537A (ja) 2022-02-14
US11883380B2 (en) 2024-01-30
EP3893870A1 (en) 2021-10-20
US20220280480A1 (en) 2022-09-08
US11364223B2 (en) 2022-06-21
ZA202104166B (en) 2023-11-29
KR20210135990A (ko) 2021-11-16

Similar Documents

Publication Publication Date Title
US11883380B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US8569325B2 (en) Method of treatment with coadministration of aspirin and prasugrel
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
EP2501381B1 (en) Treatment of atrial fibrillation
US8637566B2 (en) Slow infusion of sulcardine and its salts
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
JP2002255814A (ja) アスピリンを含有する医薬組成物
JP2004512376A (ja) 虚血性障害の処置用医薬品の製造のためのメラガトランの使用
AU2001225625A1 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
US20260041665A1 (en) J-Tp Protection
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
HK1176859A (en) Treatment of atrial fibrillation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231207

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250516

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250521

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250808

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251208

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260116

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260116